NCT06947772Not yet recruiting
Skill Building Education of Arteriovenous-Fistula Self-Care Behaviors and Quality of Life of Patients on Hemodialysis
Effectiveness of Skill Building Education on Arteriovenous Fistula Self-Care Behaviors and Quality of Life of Patients on Hemodialysis
Source: ClinicalTrials.gov · Last updated 27 Apr 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this study is to assess the effectiveness of skill building educational interventions in improving the self-care behaviors and quality of life of AVF in hemodialysis patients. This study will address questions. What is the effect of skill building education on the self-care behaviors of AVF care and quality of life in patients in patients undergoing hemodialysis treatment? A total 274 participants will be recruited from dialysis units of the study hospitals. Using random allocation 137 participants will be assigned to the control group and 137 to the intervention group. The intervention group will additionally receive a skill building education for improving their self-care behaviors and quality of life of AVF. Researcher will implement skill building educational intervention in interventional group to enhance the self-care behaviors and quality of life. This intervention have two session, first is theoretical and another one is practical. The primary outcome of this study is AVF self-care behaviors and secondary outcome is quality of life related to AVF. This outcome will be assessed using the Self-care Behaviors Scale with Arteriovenous Fistula in Hemodialysis patients (ASBHD-AVF). The secondary outcome will be assessed using the Hemodialysis Access-related Quality of Life (HARQ) which is a self-administered tool develop by Nordyke. The primary and secondary outcomes will be assessed at: baseline, after the completion of the intervention, and follow-up data will be collected at the second and sixth weeks after intervention is completed. Data will be analyzed using the Statistical Package of Social Science (SPSS) version 25. Descriptive statistics, means and standard deviations will be used for the continuous variables, while frequencies and percentages will be utilized for categorical demographic data (gender, educational level, hemodialysis frequency, items of self-care behavior scale, QOL). Normality of data will be check and applied test accordingly.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 274 (estimated)
- First submitted
- 29 Mar 2025
- Start date
- 1 May 2025
- Primary completion date
- 1 Jul 2025
- Lead sponsor
- Shifa Tameer-e-Millat University
- Diseases
- Chronic kidney disease
- NCT number
- NCT06947772
What you commit to
- Study type: Interventional
- Planned participants: 274
- From 1 May 2025 to the primary completion date, 1 Jul 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- with any visual and hearing impairment. -
Other
- The study will exclude patients:
- having any physical or mental disabilities that can interfere with their capacity to perform daily life activities.
Who the study is looking for
- Inclusion Criteria
- The study will include patients:
- diagnosed with end-stage renal disease on hemodialysis through an arteriovenous fistula
- aged 18 years or above.
- who can read and understand the Urdu language.
Age in the registry: 18 months to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Shifa College of Nursing Coordinator of this site? Confirm its status | Islamabad | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.